Overexpressing lipid raft protein STOML2 modulates the tumor microenvironment via NF-κB signaling in colorectal cancer

被引:3
作者
Gong, Hui [1 ]
Chen, Shaojing [2 ]
Liu, Shuguang [3 ]
Hu, Qianying [2 ]
Li, Yixuan [2 ]
Li, Yifan [1 ]
Li, Guiqiu [1 ]
Huang, Kaimeng [4 ,5 ]
Li, Riqing [6 ]
Fang, Lishan [2 ]
机构
[1] Shenzhen Univ, Affiliated Hosp 6, Union Shenzhen Hosp, Shenzhen Nanshan Peoples Hosp,Med Sch,Huazhong Uni, Shenzhen 518052, Guangdong, Peoples R China
[2] Sun Yat Sun Univ, Affiliated Hosp 8, Med Res Ctr, Shenzhen 518033, Peoples R China
[3] Sun Yat Sun Univ, Affiliated Hosp 8, Dept Pathol, Shenzhen 518033, Peoples R China
[4] Harvard Med Sch, Dana Farber Canc Inst, Dept Radiat Oncol, Div Radiat & Genome Stabil, Boston, MA 02215 USA
[5] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, CAS Key Lab Regenerat Biol, Guangzhou 510530, Peoples R China
[6] Shenzhen Agr Technol Promot Ctr, Shenzhen 518057, Peoples R China
基金
中国国家自然科学基金;
关键词
STOML2; Tumor microenvironment; Angiogenesis; Lipid rafts; NF-kappa B; Colorectal cancer; ANTIBODY; SAFETY;
D O I
10.1007/s00018-023-05105-y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Colorectal cancer (CRC) is characterized by a complex tumor inflammatory microenvironment, while angiogenesis and immunosuppression frequently occur concomitantly. However, the exact mechanism that controls angiogenesis and immunosuppression in CRC microenvironment remains unclear. Herein, we found that expression levels of lipid raft protein STOML2 were increased in CRC and were associated with advanced disease stage and poor survival outcomes. Intriguingly, we revealed that STOML2 is essential for CRC tumor inflammatory microenvironment, which induces angiogenesis and facilitates tumor immune escape simultaneously both in vitro and in vivo. Moreover, tumors with STOML2 overexpression showed effective response to anti-angiogenesis treatment and immunotherapy in vivo. Mechanistically, STOML2 regulates CRC proliferation, angiogenesis, and immune escape through activated NF-kappa B signaling pathway via binding to TRADD protein, resulting in upregulation of CCND1, VEGF, and PD-L1. Furthermore, treatment with NF-kappa B inhibitor dramatically reversed the ability of proliferation and angiogenesis. Clinically, we also observed a strong positive correlation between STOML2 expression and Ki67, CD31, VEGFC and PD-1 of CD8(+)T cell expression. Taken together, our results provided novel insights into the role of STOML2 in CRC inflammatory microenvironment, which may present a therapeutic opportunity for CRC.
引用
收藏
页数:16
相关论文
共 27 条
[1]   Regulation of PD-L1 Expression by NF-κB in Cancer [J].
Antonangeli, Fabrizio ;
Natalini, Ambra ;
Garassino, Marina Chiara ;
Sica, Antonio ;
Santoni, Angela ;
Di Rosa, Francesca .
FRONTIERS IN IMMUNOLOGY, 2020, 11
[2]   Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].
Brahmer, Julie R. ;
Tykodi, Scott S. ;
Chow, Laura Q. M. ;
Hwu, Wen-Jen ;
Topalian, Suzanne L. ;
Hwu, Patrick ;
Drake, Charles G. ;
Camacho, Luis H. ;
Kauh, John ;
Odunsi, Kunle ;
Pitot, Henry C. ;
Hamid, Omid ;
Bhatia, Shailender ;
Martins, Renato ;
Eaton, Keith ;
Chen, Shuming ;
Salay, Theresa M. ;
Alaparthy, Suresh ;
Grosso, Joseph F. ;
Korman, Alan J. ;
Parker, Susan M. ;
Agrawal, Shruti ;
Goldberg, Stacie M. ;
Pardoll, Drew M. ;
Gupta, Ashok ;
Wigginton, Jon M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465
[3]   Proteomic analysis of isolated membrane fractions from superinvasive cancer cells [J].
Dowling, Paul ;
Meleady, Paula ;
Dowd, Andrew ;
Henry, Michael ;
Glynn, Sharon ;
Clynes, Martin .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2007, 1774 (01) :93-101
[4]   Immunotherapy in colorectal cancer: rationale, challenges and potential [J].
Ganesh, Karuna ;
Stadler, Zsofia K. ;
Cercek, Andrea ;
Mendelsohn, Robin B. ;
Shia, Jinru ;
Segal, Neil H. ;
Diaz, Luis A., Jr. .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2019, 16 (06) :361-375
[5]   Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook [J].
Garcia, Josep ;
Hurwitz, Herbert, I ;
Sandler, Alan B. ;
Miles, David ;
Coleman, Robert L. ;
Deurloo, Regula ;
Chinot, Olivier L. .
CANCER TREATMENT REVIEWS, 2020, 86
[6]   Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities [J].
Hack, Stephen P. ;
Zhu, Andrew X. ;
Wang, Yulei .
FRONTIERS IN IMMUNOLOGY, 2020, 11
[7]   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].
Hurwitz, H ;
Fehrenbacher, L ;
Novotny, W ;
Cartwright, T ;
Hainsworth, J ;
Heim, W ;
Berlin, J ;
Baron, A ;
Griffing, S ;
Holmgren, E ;
Ferrara, N ;
Fyfe, G ;
Rogers, B ;
Ross, R ;
Kabbinavar, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342
[8]   Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity [J].
Lee, Won Suk ;
Yang, Hannah ;
Chon, Hong Jae ;
Kim, Chan .
EXPERIMENTAL AND MOLECULAR MEDICINE, 2020, 52 (09) :1475-1485
[9]   Recruitment of TNF receptor 1 to lipid rafts is essential for TNFα-mediated NF-κB activation [J].
Legler, DF ;
Micheau, O ;
Doucey, MA ;
Tschopp, J ;
Bron, C .
IMMUNITY, 2003, 18 (05) :655-664
[10]   FAP is critical for ovarian cancer cell survival by sustaining NF-κB activation through recruitment of PRKDC in lipid rafts [J].
Li, Bin ;
Ding, Zuo ;
Calbay, Ozlem ;
Li, Yue ;
Li, Tao ;
Jin, Lingtao ;
Huang, Shuang .
CANCER GENE THERAPY, 2023, 30 (04) :608-621